Novel in vitro booster vaccination to rapidly generate antigen-specific human monoclonal antibodies

• Main Authors: Sanjuan Nandin, Irene (Author), Fong, Carol (Author), Deantonio, Cecilia (Author), Torreno-Pina, Juan A. (Author), Pecetta, Simone (Author), Maldonado, Paula (Author), Gasparrini, Francesca (Author), Kjaer, Svend (Author), Borley, Daryl W. (Author), Nair, Usha (Author), Coleman, Julia A. (Author), Lingwood, Daniel (Author), Meffre, Eric (Author), Poignard, Pascal (Author), Burton, Dennis R. (Author), Batista, Facundo D. (Author), Ordovas-Montanes, Jose Manuel (Contributor), Kazer, Samuel Weisgurt (Contributor), Shalek, Alexander K (Contributor)
• Other Authors: Institute for Medical Engineering and Science (Contributor), Massachusetts Institute of Technology. Department of Chemistry (Contributor)
• Format: Article
• Language: English
• Published: Rockefeller University Press, 2018-05-16T17:00:01Z.
• Subjects: Article
• Online Access: Get fulltext

 Vaccines remain the most effective tool to prevent infectious diseases. Here, we introduce an in vitro booster vaccination approach that relies on antigen-dependent activation of human memory B cells in culture. This stimulation induces antigen- specific B cell proliferation, differentiation of B cells into plasma cells, and robust antibody secretion after a few days of culture. We validated this strategy using cells from healthy donors to retrieve human antibodies against tetanus toxoid and influenza hemagglutinin (HA) from H1N1 and newly emergent subtypes such as H5N1 and H7N9. Anti-HA antibodies were cross-reactive against multiple subtypes, and some showed neutralizing activity. Although these antibodies may have arisen as a result of previous influenza infection, we also obtained gp120-reactive antibodies from non-HIV-infected donors, indicating that we can generate antibodies without prior antigenic exposure. Overall, our novel approach can be used to rapidly produce therapeutic antibodies and has the potential to assess the immunogenicity of candidate antigens, which could be exploited in future vaccine development.